Supporting MetMAb entry into the clinic with nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) information

被引：2
|
作者：
Xiang, H. [1 ]
Reyes, A. [1 ]
Merchant, M. [2 ]
Bender, B. [3 ]
Jumbe, N. [3 ]
Young, J. [4 ]
Gelzleichter, T. [5 ]
Vaidyanathan, A. [5 ]
Peterson, A. [6 ]
Damico, L. [1 ]
机构：
[1] Genentech Inc, Early Dev PKPD, San Francisco, CA 94080 USA
[2] Genentech Inc, Canc Signaling & Translat Oncol, San Francisco, CA 94080 USA
[3] Genentech Inc, Clin PKPD, San Francisco, CA 94080 USA
[4] Genentech Inc, Assay & Automat Technol, San Francisco, CA 94080 USA
[5] Genentech Inc, Safety Assessment, San Francisco, CA 94080 USA
[6] Genentech Inc, Oncol Clin Sci ECD, San Francisco, CA 94080 USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72462-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [31] A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip
    Sung, Jong Hwan
    Kam, Carrie
    Shuler, Michael L.
    LAB ON A CHIP, 2010, 10 (04) : 446 - 455
  • [32] Pharmacokinetic/pharmacodynamic (PK/PD) relationships as applied to macrolides and related drugs: An overview
    不详
    RESEARCH IN VETERINARY SCIENCE, 2005, 78 : 20 - 21
  • [33] Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia
    Scaglione, Francesco
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 36 : S33 - S39
  • [34] Pharmacokinetic (PK) and pharmacodynamic (PD) of immunosuppressive drugs in patients awaiting for a liver tranplantation
    Kamar, Nassim
    Canivet, Cindy
    Boehler, Torsten
    Lavit, Michel
    Galvani, Sylvain
    Salvayre, Robert
    Muscari, Fabrice
    Klupp, Jochen
    Thomsen, Mogens
    Rostaling, Lionel
    TRANSPLANT INTERNATIONAL, 2007, 20 : 142 - 142
  • [35] Including baseline changes in population pharmacokinetic (PK) pharmacodynamic (PD) models.
    Lal, RA
    Young, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII89 - PII89
  • [36] Increased sensitivity to warfarin (W) with aging - A pharmacokinetic (PK) or pharmacodynamic (PD) phenomenon?
    Loebstein, R
    Peleg, D
    Almog, S
    Halkin, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P46 - P46
  • [37] Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in healthy subjects.
    Van Wart, SA
    Cirincione, BB
    Ludwig, EA
    Chen, X
    Shoaf, S
    Grasela, TH
    Mallikaarjun, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P60 - P60
  • [38] Effect of pharmacodynamic baseline changes in linked & indirect pharmacokinetic pharmacodynamic (pk-pd) models.
    Young, D
    Piscitelli, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI103 - PI103
  • [39] PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) STUDY OF MIDAZOLAM (MDZ) IN CHILDREN DURING ESOPHAGOGASTRODUODENOSCOPY (EGD)
    TOLIA, V
    KAUFFMAN, RE
    BRENNAN, S
    PEDIATRIC RESEARCH, 1990, 27 (04) : A66 - A66
  • [40] PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELING FOR METFORMIN IN HEALTHY VOLUNTEERS.
    Kim, Y.
    Cho, S.
    Lee, D.
    Son, H.
    Roh, H.
    Son, M.
    Heo, Y.
    Park, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S48 - S48
12345